DGTR hints at anti-dumping duty on Chinese ofloxacin, FinMin to decide

The commerce ministry has recommended imposition of anti-dumping duty on Chinese ofloxacin — a medicine used to treat certain infections — for five years to guard domestic players from cheap imports from the neighbouring country.

Directorate General of Trade Remedies (DGTR) has recommended the duty on imports of ‘ofloxacin’ and its intermediates from China after concluding in its probe that the product has been exported at dumped prices into India, which impacted the domestic industry.

“The authority considers it necessary and recommends imposition of the anti-dumping duty for a period of 5 years,” the directorate has said in a notification.

Ofloxacin is used to treat certain infections including bronchitis, pneumonia and infection of skin, bladder, urinary tract and prostate.

DGTR had conducted the probe following a complaint from Aarti Drugs Ltd about the dumping and initiation of the investigation.

The directorate works under the ministry.

The recommended duty ranges between USD 0.53 per kilogram and USD 7.03 per kilogram. The finance ministry takes the final call to impose these duties.

The imposition of anti-dumping duty is permissible under the World Trade Organisation (WTO) regime.

The duty is aimed at ensuring fair trading practices and creating a level-playing field for domestic producers vis-a-vis foreign producers and exporters.

Further, the department of revenue has said that the government has decided not to extend anti-dumping duty on ‘textured tempered coated and un-coated glass’ from China as recommended by the DGTR.

The directorate in May had recommended continuation of anti-dumping duty on Chinese solar glass for two years with a view to guard domestic players from cheap imports.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

supply hyperlink

What do you think?

Written by admin

Leave a Reply

Your email address will not be published. Required fields are marked *

GIPHY App Key not set. Please check settings

Gautam Gambhir To Play In Second Edition Of Legends League Cricket

“Aapne Bas Logo Ko Marna Hai”: Shoaib Akhtar Reveals Message Before Facing India For First Time